Enliven Therapeutics, Inc. (ELVN)

NASDAQ: ELVN · USD

$44.7

+1.05 (+2.4%)· Recorded snapshot

Market cap	3.3B
Net income (ttm)	-105.9M
EPS (ttm)	-$1.67
Shares out	73.3M
Volume	754,381
Beta	0.34

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Net income (ttm): -105.9M
EPS (ttm): -$1.67
Market cap: 3.3B

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Mantenere

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/En/a

P25 n/aP50 n/aP75 n/a

Trailing P/En/a

P25 n/aP50 n/aP75 n/a

ROE-15.3

P25 n/aP50 n/aP75 n/a

ROIC-11.2

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All ELVN indicators

Market & fundamental data

Available fields

174

Groups with data

Currency

USD

Showing 174 of 174 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001672619
Company name	Enliven Therapeutics, Inc.
Country	United States
Country code	US
CUSIP number	29337E102
Earnings date	2026-11-11
Earnings time	amc
Employees	67
Employees change	4
Employees growth	6.35%
Enterprise value	$2.4B
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	2016
In index	RUSSELL2000
Industry	Biotechnology
IPO date	2020-03-12
Is primary listing	Yes
Is SPAC	No
ISIN number	US29337E1029
Last 10-K release date	2026-03-03
Last earnings date	2026-08-05
Last refreshed	2026-10-28
Last stock split type	Never
Market cap	$3.3B
Market cap category	Mid-Cap
Next earnings date	2026-11-11
Options	Yes
Price	$44.74
Price currency	USD
Sector	Healthcare
SIC code	2834
Stock price date	2026-10-28
Symbol	ELVN
U.S. state	Colorado
Website	https://www.enliventherapeutics.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings yield	-3.74%
FCF / EV yield	-2.82%
FCF yield	-2.05%
P/B ratio	3.58x
Price / tangible book value	3.66x
Sector forward P/E	23.56x
Sector P/E	50.13x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Profit per employee	$-1.6M
ROA	-11%
ROA (5Y)	-21.36%
ROCE	-13.88%
ROE	-15.31%
ROE (5Y)	-33.35%
ROIC	-11.22%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth years	3
Net income growth years	0
Revenue growth years	0

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-98,000
Depreciation and amortization	$129,000
EBIT	$-124.4M
EBITDA	$-124.3M
EPS	$-1.67
FCF per share	$-0.91
Financing cash flow	$473.7M
Free cash flow	$-67M
Free cash flow minus SBC	$-107.8M
Investing cash flow	$-390.7M
Net cash flow	$16.1M
Net income	$-105.9M
Operating cash flow minus SBC	$-107.7M
Operating income	$-124.4M
Stock-based compensation	$40.8M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Book value per share	$12.22
Debt / equity	0
Long-term assets	$2.9M
Long-term liabilities	$913,000
Net cash (debt)	$893.6M
Net cash / market cap	27.3%
Net cash growth	82.41%
Net debt / equity	-1
Piotroski F-Score	2
Property, plant and equipment	$1.6M
Shareholders' equity	$895.1M
Tangible book value	$895.1M
Tangible book value per share	$12.22
Total assets	$910.2M
Total cash	$895.2M
Total debt	$1.5M
Total liabilities	$15.1M
WACC	6.1%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current assets	$907.3M
Current liabilities	$14.2M
Current ratio	64.07
Net working capital	$-1.4M
Quick ratio	63.21
Working capital	$893.2M

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-26.53%
Dividend yield	0%
Shareholder yield	-26.53%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
150-day SMA	$47.39
1D price change	2.4%
1M price change	-0.8%
1M total return	-0.8%
1W price change	7.61%
1W total return	7.61%
1Y price change	107.43%
1Y return CAGR	107.53%
1Y total return	107.43%
20-day SMA	$41.75
200-day SMA	$42.54
3M price change	-15.82%
3M total return	-15.82%
3Y price change	303.91%
3Y return CAGR	59.24%
3Y total return	303.91%
50-day SMA	$49.27
50-day SMA vs 200-day SMA	50over200
52-week high	$62.32
52-week high date	2026-08-05
52-week low	$14.79
52-week low date	2026-01-06
6M price change	-1.14%
6M total return	-1.14%
All-time high	$62.32
All-time high date	2026-08-05
All-time low	$9.80
All-time low date	2023-12-12
Average true range (ATR)	$1.92
Average volume	1.6M
Beta (1Y)	1.47
Beta (2Y)	0.91
Beta (5Y)	0.34
Change from 52-week high	-28.21%
Change from 52-week low	202.6%
Change from all-time high	-28.77%
Change from all-time low	352.96%
Change from open	2.61%
Day's gap	-0.21%
Dollar volume	$33.8M
High price	$44.88
Low price	$43.60
Monthly RSI	60.67
Open price	$43.60
Position in 52-week range	89.06%
Premarket change	0.02%
Premarket close	$43.69
Premarket price	$43.70
Premarket volume	2.5K
Previous close	$43.69
Price vs 150-day SMA	-6.33%
Price vs 20-day SMA	6.32%
Price vs 200-day SMA	4.34%
Price vs 50-day SMA	-9.91%
Relative volume	0.48
Return from IPO price	179.19%
RSI	52.08
Sharpe ratio	1.23
Sharpe ratio (3Y)	0.85
Sortino ratio	2.6
Sortino ratio (3Y)	1.61
Volume	754.4K
Weekly RSI	49.11
YTD price change	188.25%
YTD total return	188.25%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	60.5M
Float percentage	82.6%
Shares change (QoQ)	5.37%
Shares change (YoY)	26.53%
Shares held by insiders	2.69%
Shares held by institutions	100.05%
Shares outstanding	73.3M
Short % of float	17.11%
Short % of shares	14.13%
Short ratio	7.2 days

Deeper analysis on ELVN

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this ELVN report

Is a complete ELVN research report available?

No complete published report is available for Enliven Therapeutics, Inc. (ELVN) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

Enliven Therapeutics, Inc. (ELVN)

Price

Financial snapshot

Fair-value bridge

Latest news · ELVN

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All ELVN indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on ELVN

Frequently asked questions